NCT01393418

Evaluating Erythropoietin as an Indicator for Possible Kidney Injury After Cardiac Surgery

EPO: A Renal Biomarker After Cardiac Surgery

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 80 (actual)
• Sponsor: University of Michigan · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate kidney biomarkers and determine if there is a correlation between Erythropoietin (EPO) levels and acute kidney injury after cardiac surgery. An early biomarker for kidney injury may be helpful in identifying, monitoring and managing patients at risk for kidney failure after cardiac surgery. To evaluate Erythropoietin's role as a predictor of poor renal function in the immediate post-bypass period we plan to compare EPO levels to Neutrophil gelatinase-associated lipocalin (NGAL).

Detailed description

Acute kidney injury (AKI) is a serious complication after cardiac surgery and cardio-pulmonary bypass. AKI is associated with high mortality. Erythropoietin, a hormone produced by the kidneys, will be evaluated as a potential biomarker of kidney injury. Neutrophil gelatinase-associated lipocalin (NGAL) has been studied as a biomarker of kidney injury. Early kidney injury detection has been long sought and NGAL has been shown to be a promising biomarker. A troponinlike biomarker of AKI that is easily measured and capable of both early detection and risk stratification would represent an advancement in our ability to differentiate acute kidney injury from failure. Investigating EPO as a biomarker may prove to have increased predictive value in the clinical care of cardiac surgery patients.

Conditions

• Erythropoietin
• Acute Kidney Injury
• Renal Biomarker

Interventions

Type	Name	Description
OTHER	Cardiac Surgery

Timeline

• Start date: 2010-11-01
• Primary completion: 2012-03-01
• Completion: 2012-03-01
• First posted: 2011-07-13
• Last updated: 2016-12-15

Locations

1 site across 1 country: United States